Lancet for Prana

A recent clinical trial has shown that PBT2 improves executive function and lowers spinal Abeta levels in Alzheimer's patients

The data from clinical trials of Prana Biotechnology's [ASX: PBT] Phase IIa clinical trials of PBT2 in Alzheimer's patients has been published in the Lancet Neurology journal.

The data shows that PBT2 was able to improve executive function in patients with early stage Alzheimer's disease. PBT2 works also reduces Abeta levels in the spinal fluid of patients.

The 78 trial participants experienced no serious adverse effects. The data shows that Abeta levels were reduced by an average of 13 per cent.

The data from Prana's earlier preclinical trials was recently published in Neuron.

Comments